迪哲医药 中国首个独立研发在美获批的全球首创新药诞生 7月3日，迪哲医药宣布舒沃哲® （ZEGFROVY®，通用名：舒沃替尼片） 的新药上市申请，正式获得美国食 品药品监督管理局 （FDA） 批准，用于既往经含铂化疗治疗时或治疗后出现疾病进展，并且经FDA批准的 试剂盒检测确认，存在表皮生长因子受体 （EGFR） 20号外显子插入突变 （exon20ins） 的局部晚期或转移性 非小细胞肺癌 （NSCLC） 的成人患者。 舒沃哲®通过优先审评程序获得批准上市， 成为目前全球首个且唯一在美获批的EGFR exon20ins NSCLC国 创新药 。其在分子设计的源头进行了重大创新，突破难治靶点，是 中国首个独立研发在美获批的全球首创 新药 。 力品药业 挑战原研专利成功！力品药业阿尔茨海默高端制剂获FDA批准 7月15日，由力品药业自主研发的盐酸美金刚多奈哌齐缓释胶囊获得美国FDA批准，用于治疗中重度阿尔茨 海默病。 这是国内首个通过Paragraph IV专利挑战成功上市的阿尔茨海默病复方缓释制剂。 阿尔茨海默病 （AD） 是一种中枢神经系统退行性疾病，主要发生于老年及老年前期人群。随着老龄化进程 加速，目前 ...

Group 1 - Xiamen has prioritized the implementation of the central eight regulations, focusing on addressing grassroots and public issues through concentrated rectification efforts [1] - A total of 2,805 issues were identified, with 4,860 corrective measures formulated, demonstrating a systematic approach to problem-solving [1] - Key areas of focus include alleviating pressure on grassroots reception and addressing issues related to elderly care, campus meals, property management, and medical insurance [1] Group 2 - The healthcare sector is a significant focus, with the Xiamen Health Commission implementing seven specific measures to optimize medical services [2] - Initiatives include the "Thousand Doctors Down to the Community" program, improving access to quality medical resources for residents [2] - The introduction of a "credit medical" model has reduced average waiting times for patients by 35 minutes, enhancing the overall healthcare experience [2] Group 3 - The satisfaction rate for school meal services in Xiamen reached 94.5%, indicating positive feedback from the community [3] - Approximately 20 million yuan in overdue village collective asset rents has been recovered, showcasing effective financial management [3] - The launch of an online refund feature for outpatient prepayments has been well-received, improving convenience for the public [3]

Core Insights - The company, BGI Genomics, reported a significant decline in its financial performance for 2024, with a net profit loss of 903 million yuan, marking its first annual net loss since its listing and the largest loss to date [1][2] Financial Performance - BGI Genomics achieved a revenue of 3.867 billion yuan in 2024, a year-on-year decrease of 11.10% [1] - The net profit attributable to shareholders was a loss of 903 million yuan, representing a staggering year-on-year decline of 1071.68% [1][2] - The company's net profit had peaked at 2.09 billion yuan in 2020, but has been on a downward trend since, with profits of 1.462 billion yuan in 2021, 803 million yuan in 2022, and 93 million yuan in 2023 [2] - Total assets decreased to 12.542 billion yuan, down 7.87% year-on-year, while net assets attributable to shareholders fell to 9.135 billion yuan, a reduction of 7.35% [2] Business Segment Performance - The infection prevention business saw a dramatic revenue drop of 85.91%, with earnings of only 73 million yuan in 2024 compared to 516 million yuan in 2023 [3] - Despite the downturn in the infection prevention segment, the reproductive health and oncology businesses maintained growth, with the precision medicine testing solutions segment showing a 22.37% increase when excluding the impact of public health events [3] Industry Outlook - The global genetic testing market is projected to grow from 19.66 billion USD in 2024 to 32.83 billion USD by 2029, with a compound annual growth rate of 10.81% [4] - The company plans to increase investments in medical AI models, intelligent testing platforms, and integrated multi-omics technologies to enhance its core competitiveness and adapt to market changes [4]